Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AKT3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AKT3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/AKT3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AKT3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075697 | Prostate | BPH | cell aging | 45/3107 | 132/18723 | 7.00e-07 | 1.35e-05 | 45 |
GO:00435429 | Prostate | BPH | endothelial cell migration | 73/3107 | 279/18723 | 3.03e-05 | 3.46e-04 | 73 |
GO:00181059 | Prostate | BPH | peptidyl-serine phosphorylation | 79/3107 | 315/18723 | 7.09e-05 | 6.96e-04 | 79 |
GO:00105946 | Prostate | BPH | regulation of endothelial cell migration | 61/3107 | 232/18723 | 1.13e-04 | 1.03e-03 | 61 |
GO:00105956 | Prostate | BPH | positive regulation of endothelial cell migration | 39/3107 | 133/18723 | 1.73e-04 | 1.48e-03 | 39 |
GO:00182097 | Prostate | BPH | peptidyl-serine modification | 82/3107 | 338/18723 | 1.73e-04 | 1.48e-03 | 82 |
GO:00506796 | Prostate | BPH | positive regulation of epithelial cell proliferation | 54/3107 | 207/18723 | 3.33e-04 | 2.52e-03 | 54 |
GO:00903982 | Prostate | BPH | cellular senescence | 29/3107 | 93/18723 | 3.66e-04 | 2.71e-03 | 29 |
GO:0045793 | Prostate | BPH | positive regulation of cell size | 7/3107 | 11/18723 | 6.10e-04 | 4.16e-03 | 7 |
GO:19013424 | Prostate | BPH | regulation of vasculature development | 78/3107 | 348/18723 | 2.76e-03 | 1.46e-02 | 78 |
GO:00083617 | Prostate | BPH | regulation of cell size | 45/3107 | 181/18723 | 2.79e-03 | 1.47e-02 | 45 |
GO:00457654 | Prostate | BPH | regulation of angiogenesis | 76/3107 | 342/18723 | 3.90e-03 | 1.95e-02 | 76 |
GO:00435343 | Prostate | BPH | blood vessel endothelial cell migration | 43/3107 | 176/18723 | 4.79e-03 | 2.29e-02 | 43 |
GO:00435363 | Prostate | BPH | positive regulation of blood vessel endothelial cell migration | 22/3107 | 76/18723 | 4.96e-03 | 2.34e-02 | 22 |
GO:006024910 | Prostate | BPH | anatomical structure homeostasis | 68/3107 | 314/18723 | 1.10e-02 | 4.53e-02 | 68 |
GO:005067316 | Prostate | Tumor | epithelial cell proliferation | 125/3246 | 437/18723 | 2.56e-09 | 1.08e-07 | 125 |
GO:004887219 | Prostate | Tumor | homeostasis of number of cells | 86/3246 | 272/18723 | 5.29e-09 | 2.11e-07 | 86 |
GO:005067815 | Prostate | Tumor | regulation of epithelial cell proliferation | 110/3246 | 381/18723 | 1.32e-08 | 4.82e-07 | 110 |
GO:009013217 | Prostate | Tumor | epithelium migration | 105/3246 | 360/18723 | 1.57e-08 | 5.62e-07 | 105 |
GO:009013017 | Prostate | Tumor | tissue migration | 106/3246 | 365/18723 | 1.73e-08 | 6.10e-07 | 106 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AKT3 | SNV | Missense_Mutation | novel | c.453N>C | p.Leu151Phe | p.L151F | Q9Y243 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
AKT3 | SNV | Missense_Mutation | rs772090769 | c.793N>A | p.Gly265Arg | p.G265R | Q9Y243 | protein_coding | tolerated(0.67) | benign(0) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
AKT3 | SNV | Missense_Mutation | | c.1118N>G | p.Ala373Gly | p.A373G | Q9Y243 | protein_coding | tolerated(0.09) | benign(0.117) | TCGA-AC-A2FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
AKT3 | SNV | Missense_Mutation | | c.928C>G | p.Pro310Ala | p.P310A | Q9Y243 | protein_coding | deleterious(0.01) | probably_damaging(0.977) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
AKT3 | SNV | Missense_Mutation | | c.1421C>T | p.Ser474Phe | p.S474F | Q9Y243 | protein_coding | tolerated(0.05) | possibly_damaging(0.783) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
AKT3 | SNV | Missense_Mutation | | c.250N>A | p.Glu84Lys | p.E84K | Q9Y243 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AKT3 | SNV | Missense_Mutation | novel | c.47G>C | p.Gly16Ala | p.G16A | Q9Y243 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-4J-AA1J-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
AKT3 | SNV | Missense_Mutation | | c.629C>T | p.Ser210Phe | p.S210F | Q9Y243 | protein_coding | deleterious(0.01) | benign(0.285) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
AKT3 | SNV | Missense_Mutation | | c.1212N>G | p.Phe404Leu | p.F404L | Q9Y243 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
AKT3 | SNV | Missense_Mutation | | c.164C>T | p.Ser55Leu | p.S55L | Q9Y243 | protein_coding | tolerated(0.05) | benign(0.16) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565578 | IPATASERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | GSK2126458 | OMIPALISIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565585 | UPROSERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | Afuresertib | AFURESERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | MK2206 | MK-2206 | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | BAY1125976 | | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | GSK2141795 | UPROSERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | allosteric modulator | 328083529 | MIRANSERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL494089 | GSK-690693 | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | PERIFOSINE | PERIFOSINE | |